Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Sara Lonardi et al.|The Lancet Oncology|2016Cited by 1k
Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upRalf‐Dieter Hofheinz, Erika Martinelli, E Fokas et al.|Annals of Oncology|2025Cited by 122